Mitral valve treatment firm NewMed Medical closes multi-million-dollar Series B financing

NewMed Medical, a company specializing in mitral valve interventional treatment devices, has received tens of millions of dollars in Series B financing round from OrbiMed Capital. The proceeds will be used to promote the clinical testing and registration of the first mitral valve replacement interventional valve in China.

NewMed Medical, a company specializing in mitral valve interventional treatment devices, has received tens of millions of dollars in Series B financinground from OrbiMedCapital. The proceeds will be used to promote the clinical testing and registration of the first mitral valve replacement interventional valve in China.

Established in March 2015, NewMed Medical is a developer of artificial heart valves and transcather implantation systems. The company’s products used to replace the diseased mitral valve, simplify the heart valve replacement surgery and reduce the risks of treatment, enabling patients to recover faster, and save surgery expenses.

Prior to this, NewMed Medical received three rounds of financing. In March 2016, the angel round of funding was completed; April 2018, Series A financing of tens of millions of yuan; July 2018, Series A+ financing round completed.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/07/mitral-valve-treatment-firm-newmed-medical-closes-multi-million-dollar-series-b-financing/.

Leave a Reply

Please Login to Comment